ALSO NOTED: Ariad selling shares; Indevus gains milestone; Barr closing on Pliva; and much more...

> Ariad Pharmaceuticals is selling 3.1 million shares in a public offering. Report

> Indevus Pharmaceuticals has received a $10 million milestone payment from Esprit Pharma, the company's partner in the U.S. for Sanctura and and Sanctura XR. Release

> Barr Pharmaceuticals has now acquired 92 percent of Pliva's shares, putting it on track to close the takeover next month. Report

> Dutch biotech AM-Pharma is touting positive results for its pilot study in treating sepsis with its Alkaline Phosphatase drug. Release

And Finally… Scientists helped add 30 years to the average life span over the past century. Now they're focusing on adding vitality to a longer life. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.